Efficacy of sodium stibogluconate alone and in combination with allopurinol for treatment of mucocutaneous leishmaniasis

Clinical Infectious Diseases

Volumn 25, Issue 3, 1997, Pages 677-684

  Llanos Cuentas, Alejandro ^a   Echevarría, Juan ^b   Cruz, Maria ^b   La Rosa, Alberto ^b   Campos, Pablo ^b   Campos, Miguel ^b   Franke, Eileen ^b   Berman, Jonathan ^b   Modabber, Farrokh ^b   Marr, Joseph ^b  

^a INSTITUTO DE MEDICINA TROPICAL ALEXANDER VON HUMBOLDT   (Peru)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALLOPURINOL; ASPARTATE AMINOTRANSFERASE; STIBOGLUCONATE SODIUM;

ADULT; ANEMIA; ARTHRALGIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; FEMALE; HEADACHE; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MYALGIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN LEISHMANIASIS; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0030800901     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/513776     Document Type: Article

References (12)

1. Marsden PD. Mucosal leishmaniasis ("espundia" Escomel, 1911). Trans R Soc Trop Med Hyg 1986; 80:859-76.
2. Walton BC. American cutaneous and mucocutaneous leishmaniasis. In: Peters W, Killick-Kendrick R, eds. The leishmaniasis in biology and medicine. Vol 2. London: Academic Press, 1987:637-64.
3. Bryceson ADM. Leishmaniasis. In: Cook GC, ed. Manson's tropical diseases. 20th ed. Philadelphia: WB Saunders, 1996:1213-45.
4. WHO Expert Committee. Control of the leishmaniases. World Health Organ Techn Rep Ser 1990; 793:53.
5. Llanos-Cuentas EA, Echevarria J, Cruz M, Campos M. A score of mucous involvement as a predictor of relapse in 50 patients with cutaneous leishmaniasis treated with pentavalent antimony [abstract no MoP-7-12]. In: Abstracts of 12th International Congress for Tropical Medicine and Malaria. Amsterdam: International Society of Tropical Medicine and Malaria, 1988:54.
6. Llanos-Cuentas A. Tratamiento de leishmaniasis mucosa: Analisis de los factores asociados con la respuesta terapeutica a los antimoniales pentavalentes [thesis]. Lima, Peru: Escuela de Post-Grado "Victor Alzamora Castro" de la Universidad Peruana Cayetano Heredia, 1991.
7. Bryceson A. Therapy in man. In: Peters W, Killick-Kendrick R, eds. The leishmaniasis in biology and medicine. Vol 2. London: Academic Press, 1987:847-908.
8. Nelson DJ, LaFon SW, Tuttle JV, et al. Allopurinol ribonucleoside as an antileishmanial agent: biological effects, metabolism, and enzymatic phosphorylation. J Biol Chem 1979; 254:11544-9.
9. Kager PA, Rees PH, Wellde BT, Hockmeyer WT, Lyerly WH. Allopurinol in the treatment of visceral leishmaniasis. Trans R Soc Trop Med Hyg 1981; 75:556-9.
10. Chunge CN, Gachihi G, Muigai R, et al. Visceral leishmaniasis unresponsive to antimonial drugs. III. Successful treatment using a combination of sodium stibogluconate plus allopurinol. Trans R Soc Trop Med Hyg 1985; 79:715-8.
11. Martinez S, Marr JJ. Allopurinol in the treatment of American cutaneous leishmaniasis. N Engl J Med 1992; 326:741-4.
12. Momeni AZ, Aminjavaheri M. Treatment of recurrent cutaneous leishmaniasis. Int J Dermatol 1995; 34:129-33.